SCHEMBL487169

SCHEMBL487169

CC(C)c1ccc(O)c(O)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 6/20 0.56
GABRB2 P47870 4/20 0.56
GABRB1 P18505 4/20 0.56
LMNA P02545 2/20 0.56
SLC6A2 P23975 2/20 0.56
HTR2B P41595 2/20 0.56
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
FAAH O00519 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
HPGD P15428 1/20 0.56
TSHR P16473 1/20 0.56
GABRG2 P18507 1/20 0.56
PTGS1 P23219 1/20 0.56
HTR2C P28335 1/20 0.56
GABRB3 P28472 1/20 0.56
GABRA5 P31644 1/20 0.56
GABRA3 P34903 1/20 0.56
GABRA2 P47869 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2585105 0.89 GABRA1 (0.68) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL29699645 0.89 GABRA1 (0.68) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL9614891 0.84 ADRB2 (0.39) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL24217828 0.82 ADRB2 (0.42) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL30046916 0.82 ADRB2 (0.42) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL25221643 0.82 GABRA1 (0.54) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL2989000 0.82 ADRB2 (0.42) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL11038353 0.80 GABRA1 (0.52) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL6679675 0.80 GABRA1 (0.52) GABRA1GABRB2GABRB1LMNASLC6A2
SCHEMBL6015493 0.80 GABRA1 (0.46) GABRA1GABRB2GABRB1LMNASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12044968-B2 Protective film-forming composition having acetal structure and amide structure NISSAN CHEMICAL CORPORATION (JP) 2024-07-23 US disclosed
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders Smilebiotek Zhuhai Limited (CN) 2024-06-25 US disclosed
WO-2022098879-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-12 WO disclosed
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-05 US disclosed
US-11236082-B2 EZH2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-01 US disclosed
US-20220015338-A1 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS Smilebiotek Zhuhai Limited (CN) 2022-01-20 US disclosed
US-11214715-B2 Ionic polymers and their use as wet-adhesives and coatings ACatechol, Inc. (US) 2022-01-04 US disclosed
CN-113260921-A Photosensitive resin composition, dry film, photosensitive dry film, resist film, substrate with mold, and method for producing plated molded article 东京应化工业株式会社 2021-08-13 CN disclosed
US-20200409260-A1 PROTECTIVE FILM FORMING COMPOSITION HAVING AN ACETAL STRUCTURE NISSAN CHEMICAL CORPORATION (JP) 2020-12-31 US disclosed
CN-211964115-U Mixed gas oxidation production system 上海优合生物科技有限公司 2020-11-20 CN disclosed
US-20060029811-A1 mixing a phenolic compound containing the inorganic microfine particle(SiO2) and a compound containing at least one of the glycidyl group and/or an epoxy group containing the inorganic microfine particle; fireproofing; good mechanical properties; heat resistance; automobiles, construction, electronics NIPPON SHOKUBAI CO., LTD. (JP) 2006-02-09 US disclosed
CN-1730548-A Resin composition, method for producing same, and cured product NIPPON CATALYTIC CHEM IND (JP) 2006-02-08 CN disclosed
US-6878659-B2 Solid catalyst component for olefin polymerization and catalyst TOHO TITANIUM CO., LTD. (JP) 2005-04-12 US disclosed
EP-1507829-A1 FIRE RETARDANT RESIN COMPOSITION, METHOD OF ITS PRODUCTION, SHAPED ARTICLES COMPRISING THE SAME, AND SILICA Nippon Shokubai Co., Ltd. (JP) 2005-02-23 EP disclosed
US-20040072681-A1 Solid catalyst component for olefin polymerization and catalyst TOHO TITANIUM CO., LTD. (JP) 2004-04-15 US disclosed
WO-2003099934-A1 FIRE RETARDANT RESIN COMPOSITION, METHOD OF ITS PRODUCTION, SHAPED ARTICLES COMPRISING THE SAME, AND SILICA NIPPON SHOKUBAI CO., LTD. (JP) 2003-12-04 WO disclosed
EP-1260524-A1 SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST Toho Titanium Co., Ltd. (JP) 2002-11-27 EP disclosed
US-4842983-A PHENOLIC RESOLE MIXED WITH LIGHT SENSITIVE SUBSTANCE OR REACTED WITH QUINONE DIAZIDE SULFONYL HALIDE FUJI PHOTO FILM CO., LTD. (JP) 1989-06-27 US disclosed
US-4732840-A LITHOGRAPHY FUJI PHOTO FILM CO., LTD. (JP) 1988-03-22 US disclosed
EP-0196031-A2 Light-sensitive compositions and light-sensitive materials FUJI PHOTO FILM CO., LTD. (JP) 1986-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders MB, MYOC, PDE6A GABRA1 2619/4885GABRB2 2081/4885GABRB1 2034/4885
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 GABRA1 2343/4885GABRB2 2204/4885GABRB1 1983/4885
US-20220015338-A1 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS MB, MYOC, PDE6A GABRA1 2619/4885GABRB2 2081/4885GABRB1 2034/4885
US-11236082-B2 EZH2 inhibitors and uses thereof EZH2, EZH1, BMI1 GABRA1 3067/4885GABRB2 2512/4885GABRB1 2489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.